George Selby is an Oncology physician affiliated with University of Oklahoma Health Sciences Center. OpenAlex indexes 177 publications with 2,969 citations (h-index 24); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
825 NE 10th St
Oupb 5200
Oklahoma City, OK 731045417
Telephone
405-271-8299Registry record last updated 8 Jul 2007.
Clinical trials
- Intensive Combo Chemo With Autologous BM Rescue for Metastatic Breast Cancer
Sponsor: University of Oklahoma
- High Dose Chemo With Autologous BMT for Treatment of Metastatic Breast Cancer
Sponsor: University of Oklahoma
- Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases
Sponsor: University of Oklahoma
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
41.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor41.9%Acyclovir100%Part D<11 patientsMusculoskeletal
24.3%Xanthine oxidase inhibitor24.3%Allopurinol100%Part D<11 patientsCancer & immunology
17.6%Kinase inhibitor17.6%Jakafi100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1990–1990 per NIH RePORTER. The latest:
- T-LYMPHOCYTE DEPLETION BY PURINE METABOLISM INHIBITORS
University of Oklahoma Hlth Sciences Ctr
FY1990S07RR005411
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center
Bone Marrow Transplantation
2022 - Azacitidine Maintenance Therapy Post-Allogeneic Stem Cell Transplantation in Poor-Risk Acute Myeloid Leukemia
Hematology/Oncology and Stem Cell Therapy
2021 - Integration of Publicly Reported Center Outcomes into Standards and Accreditation: The FACT Model
Biology of Blood and Marrow Transplantation
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Ira Targoff, MD
University of Oklahoma Health Sciences Center
Harold Burkhart, MD
University of Oklahoma Health Sciences Center
Steven Chernausek, MD
University of Oklahoma Health Sciences Center
Udho Thadani, MD
University of Oklahoma Health Sciences Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”